Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities

Narli Ozdemir Z., Kilicaslan N. A., Yilmaz M., EŞKAZAN A. E.

INTERNATIONAL JOURNAL OF HEMATOLOGY, cilt.117, sa.1, ss.3-15, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 117 Sayı: 1
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1007/s12185-022-03446-1
  • Dergi Adı: INTERNATIONAL JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.3-15
  • Anahtar Kelimeler: Chronic myeloid leukemia, National comprehensive cancer network, European LeukemiaNet, Tyrosine kinase inhibitors, Treatment-free remission, STEM-CELL TRANSPLANTATION, TYROSINE KINASE INHIBITORS, CHRONIC MYELOGENOUS LEUKEMIA, ARTERIAL OCCLUSIVE DISEASE, MOLECULAR RESPONSE, IMATINIB MESYLATE, CML PATIENTS, GENERIC IMATINIB, DOMAIN MUTATIONS, MARROW FIBROSIS
  • İstanbul Üniversitesi Adresli: Hayır

Özet

Patients diagnosed with chronic myeloid leukemia (CML) in chronic phase can now have a life expectancy comparable to that of the general population thanks to the use of tyrosine kinase inhibitor (TKI) therapies. Although most patients with CML require lifelong TKI therapy, it is possible for some patients to achieve treatment-free remission. These spectacular results have been made possible by the development of superior treatment modalities as well as clinicians' efforts in strictly adhering to clinical guidelines such as the National Comprehensive Cancer Network (NCCN) and European Leukemia Network (ELN). CML treatment recommendations reported in these guidelines are the result of years of selecting and incorporating the most reliable evidence. In this review, we provide a synopsis of the differences and similarities that exist between the NCCN and ELN guidelines.